Lyudmila A. Bazhenova, MD

Dr Bazhenova discusses the FDA approval of sunvozertinib for patients with EGFR-mutated metastatic non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses ways that sunvozertinib expands the treatment paradigm for EGFR-mutated metastatic non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses updated efficacy data from the TRUST-I study of taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses steps that the lung cancer field can take to improve biomarker research.

The panel concludes the discussion with key takeaways on the evolving treatment landscape in HER2 non–small cell lung cancer.

Experts on HER2 NSCLC provide clinical insights on selecting between antibody-drug conjugates and TKIs, treatment sequencing, and the role of chemoimmunotherapy.

The expert panel shares its thoughts on current challenges and unmet needs in the overall HER2-mutated non–small cell lung cancer treatment landscape.

D. Ross Camidge, MD, PhD, discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer.

Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.

The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.

Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, an expert on non–small cell lung cancer, provides clinical insights on the management of adverse events associated with antibody-drug conjugates.

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.

Experts on HER2-mutated NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.

Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2-mutated non–small cell lung cancer.

Experts on HER2-mutated non–small cell lung cancer provide clinical insights on biomarker testing challenges and the role of reflex testing.

A panel of thoracic oncologists introduce themselves and discuss biomarker testing strategies and the diagnosis of HER2-mutated non–small cell lung cancer (NSCLC).

Lyudmila A. Bazhenova, MD, discusses key factors in the management of unresectable non–small cell lung cancer, emphasizing the importance of understanding and performing biomarker testing in this population.

Lyudmila A. Bazhenova, MD, discusses factors to consider when navigating the use of neoadjuvant vs adjuvant EGFR– and ALK-directed treatment strategies for patients with non–small cell lung cancer who express oncogenic drivers.

Lyudmila A. Bazhenova, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, expanding on the hope to confirm a consensus on how to best move forward to address gaps in lung cancer care.

Lyudmila A. Bazhenova, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, emphasizing the importance of collaborative efforts when approaching gaps in lung cancer care.

Lyudmila A. Bazhenova, MD, discusses how to treat patients with non–small cell lung cancer who present with EGFR mutations, highlights how to accurately pinpoint gaps in lung cancer care, and expands on how to address these gaps in patients with non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses potential combination strategies with KRAS G12C inhibitors in advanced non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses the challenges of second-line therapy in small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses NTRK inhibition with larotrectinib and entrectinib in patients with NTRK fusion–positive non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses future research questions with fam-trastuzumab deruxtecan-nxki in HER2-mutated lung cancer.

Lyudmila A. Bazhenova, MD, discusses the importance of testing for HER2 mutations in lung cancer.

Lyudmila A. Bazhenova, MD, discusses the results of a preliminary exploratory correlative analysis of the phase 1/2 KRYSTAL-1 trial in advanced non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses ongoing clinical trials in non–small cell lung cancer that are investigating the utility of immunotherapy.